The article below may contain offensive and/or incorrect content.
The prototype 5-HT2A receptor agonist hallucinogens LSD, mescaline, and psilocybin are classified as Schedule 1 drugs of abuse by the U.S. Drug Enforcement Administration. Accumulating clinical evidence has also suggested that acute or repeated "microdosing" with these drugs may have utility for treatment of some mental health disorders, including drug abuse and depression. The goal of the present study was to evaluate LSD, mescaline, and psilocybin effects on intracranial self-stimulation (ICSS), a procedure that has been used to evaluate abuse-related effects of other classes of abused drugs. Effects of repeated LSD were also examined to evaluate potential changes in its own effects on ICSS or changes in effects produced by the abused psychostimulant methamphetamine or the prodepressant kappa opioid receptor (KOR) agonist U69,593. Male Spragueâ€"Dawley rats were implanted with microelectrodes targeting the medial forebrain bundle and trained to respond under a "frequency-rate" ICSS procedure, in which many drugs of abuse increase (or "facilitate") ICSS. In acute dose-effect and time-course studies, evidence for abuse-related ICSS facilitation was weak and inconsistent; the predominant effect of all 3 drugs was dose- and time-dependent ICSS depression. Repeated LSD treatment failed to alter either its own ICSS depressant effects or the abuse-related effects of methamphetamine; however, repeated LSD did attenuate ICSS depression by U69,593. These results extend those of previous preclinical studies to suggest weak expression of abuse-related effects by 5-HT2A agonist hallucinogens and provide supportive evidence for therapeutic effects of repeated LSD dosing to attenuate KOR-mediated depressant effects but not abuse potential of psychostimulants. (PsycINFO Database Record (c) 2019 APA, all rights reserved)
Previous Site
Departments
Authors
Libraries
Current Articles
- Article Correctness Is Author's Responsibility: Scientific Meeting » Workshop: Gene-based Therapeutics for Rare Genetic Neurodevelopmental Psychiatric Disorders
- Article Correctness Is Author's Responsibility: Guiding gender-atypical kids through puberty
- Article Correctness Is Author's Responsibility: Pandemic worsens child mental health crisis
- Article Correctness Is Author's Responsibility: Being heard is more important to some people than following COVID-19 regulations
- Article Correctness Is Author's Responsibility: Workaholics at a greater risk of depression
- Article Correctness Is Author's Responsibility: Can kids have seasonal affective disorder?
- Article Correctness Is Author's Responsibility: Video » NIMH Expert Dr. Krystal Lewis Discusses Managing Stress & Anxiety
- Article Correctness Is Author's Responsibility: Scientific Meeting » NIMH Livestream Event: Managing Stress and Anxiety
- Article Correctness Is Author's Responsibility: A third of Americans don't see systemic racism as a barrier to good health
- Article Correctness Is Author's Responsibility: The challenge of pandemic fatigue is hitting people hard
- Article Correctness Is Author's Responsibility: How and why to take a break from the news
- Article Correctness Is Author's Responsibility: What brain imaging tells us about decluttering our minds
- Article Correctness Is Author's Responsibility: Blog Post » Showing Support for Basic Researchers
- Article Correctness Is Author's Responsibility: How to reduce news-related stress for better mental health
- Article Correctness Is Author's Responsibility: Five myths about loneliness
- Article Correctness Is Author's Responsibility: How to help someone struggling with suicidal ideation
- Article Correctness Is Author's Responsibility: Better sleep hygiene is crucial when you're anxious
- Article Correctness Is Author's Responsibility: How to remotivate kids for more distance learning
- Article Correctness Is Author's Responsibility: How to set goals you’ll actually achieve
- Article Correctness Is Author's Responsibility: To 'keep sharp' this year, keep learning